Orbis Signs Novo Macrocycle Alliance Worth Up to $1.4B

Orbis Medicines, a Lilly-backed biotech, entered an alliance with Novo announced Thursday morning worth up to $1.4 billion to design macrocycle drugs for cardiometabolic diseases.

Orbis Medicines has struck a drug discovery alliance with Novo worth as much as $1.4 billion, putting its macrocycle chemistry platform to work on cardiometabolic disease targets. The pact was announced Thursday morning, and it lands with Orbis already carrying a notable backer on its shareholder register: Eli Lilly (NYSE: LLY), whose shares last closed at 1137.82, up 0.15% on the day. Novo (NYSE: NVO) last closed at 41.71, down 1.93%, according to market data as of 20:00 GMT on 16 September 2026.

The headline number — up to $1.4 billion — is the kind of figure that needs unpacking. In discovery-stage alliances of this shape, the overwhelming majority of the total is contingent: research funding and a modest upfront payment at signing, then preclinical, clinical, regulatory and sales milestones that only pay out if molecules survive each gate. Orbis and Novo have not broken the total into upfront versus milestone components in the terms disclosed so far, and the biotech is being paid, first and foremost, for chemistry rather than for a finished asset.

What a macrocycle actually is, and why Novo wants them

Macrocycles are large ring-shaped molecules. Their appeal is that they sit in the gap between the two dominant classes of medicine. Antibodies are big, specific and potent, and can grip targets that conventional pills bounce off — but they have to be injected and cannot get inside cells easily. Small molecules are cheap to make and can be swallowed, but they struggle with the flat, featureless protein surfaces that matter in metabolic signalling.

A macrocycle, in principle, marries the two: the binding surface area of a biologic with the manufacturability and, in the best cases, the oral dosing of a small molecule. That last point is the commercial prize in cardiometabolic medicine right now. The category's biggest franchises are injectables, and the race to make them pills has become the defining competitive question of the field. A chemistry platform that credibly widens the set of targets reachable by an oral drug is worth paying for on option value alone.

As Endpoints News reported, Orbis will help Novo generate macrocycles aimed at cardiometabolic diseases — the cluster of conditions spanning obesity, type 2 diabetes, dyslipidaemia, hypertension and their cardiovascular and renal consequences.

The awkward geometry of a Lilly-backed partner working with Novo

The most striking feature of the deal is not the money. It is that a company counting Lilly among its investors has signed a discovery alliance with Lilly's fiercest rival in metabolic disease. That combination is more common than it looks, and it says something useful about how large pharma now buys innovation.

Corporate venture arms typically take minority, non-controlling stakes and explicitly do not secure exclusivity or right of first refusal over everything the portfolio company does. The point of the investment is early visibility into a platform and a seat near the science, not a lock on it. A platform company, meanwhile, has every incentive to run multiple partnerships: each one validates the technology, funds the engine and reduces dependence on any single counterparty.

For Orbis, the read-through is favourable on both counts. Having Lilly money on the cap table and a Novo research alliance on the books is a stronger position than having either alone, because it tells prospective partners the chemistry has been examined closely by two of the most sophisticated buyers in the category.

Why Novo is buying discovery chemistry rather than assets

Deals like this sit at the cheap end of the business development spectrum. A late-stage asset costs billions in cash at signing; a discovery collaboration costs a research budget and a promise. Novo is buying a set of shots on goal, priced so that it only pays in full if those shots convert years from now.

That matters more than usual for Novo, whose dominance in metabolic disease rests on a franchise now facing the most crowded pipeline environment the sector has seen. Restocking the early pipeline with mechanisms that are structurally differentiated — rather than another entrant in an established class — is the defensive logic here. Orbis's contribution is access to target space that conventional medicinal chemistry has treated as undruggable.

The market is not pricing any of this yet, and should not be. Novo's 1.93% decline into the most recent close is noise relative to a discovery alliance whose first molecule is years from a clinic. For comparison, the S&P 500 tracker (SPY) closed at $754.05, down 0.44%, the Nasdaq 100 tracker (QQQ) at $704.72, up 0.03%, and the Dow 30 tracker (DIA) at $515.22, down 1.15%. Discovery-stage news moves private valuations; it rarely moves a large-cap pharma tape.

The milestones that will decide whether $1.4 billion means anything

Three checkpoints will determine whether the headline figure ever becomes real cash for Orbis.

• Target selection and hit generation. The first test is whether Orbis's platform produces macrocycles that bind the agreed cardiometabolic targets with the potency Novo needs. This is where most discovery alliances quietly stall.
• Oral bioavailability. Macrocycles can be designed to be swallowed, but the chemistry is unforgiving — ring size, rigidity and membrane permeability fight each other. If the output is injectable-only, much of the strategic rationale thins out.
• Candidate nomination and expansion. Watch for whether Novo widens the target list or exercises options beyond the initial scope. An expansion is the clearest possible signal that the chemistry worked; silence at renewal is the clearest signal that it did not.

For the wider sector, the deal is another data point in a steady shift: large pharma increasingly rents specialised chemistry and biology platforms rather than building them, paying in staged milestones that transfer execution risk to the smaller party. Orbis keeps its independence and its platform. Novo gets optionality on target classes it could not otherwise reach. The $1.4 billion sits mostly in the future, contingent on molecules that do not exist yet — which is precisely why both sides could sign it.

Key facts

• Deal value: Up to $1.4 billion for Orbis Medicines
• Therapeutic focus: Cardiometabolic diseases, via macrocycle molecules
• NVO last close: 41.71, -1.93% (as of 20:00 GMT, 16 Sep 2026)
• LLY last close: 1137.82, +0.15% (as of 20:00 GMT, 16 Sep 2026)

Frequently asked questions

What did Orbis Medicines agree with Novo?

Orbis Medicines entered a drug discovery alliance with Novo worth up to $1.4 billion, announced Thursday morning. Under the pact, Orbis will help Novo create macrocycle molecules aimed at cardiometabolic diseases. The disclosed terms describe a total potential value rather than a breakdown of upfront cash versus contingent milestone payments.

What is a macrocycle drug?

A macrocycle is a large, ring-shaped molecule that combines features of antibodies and small molecules. It offers the broad binding surface of a biologic, which lets it engage protein targets conventional pills cannot grip, while remaining potentially manufacturable and in some cases orally dosed like a small molecule.

Why does it matter that Orbis is Lilly-backed?

Eli Lilly is an investor in Orbis and also Novo's main competitor in metabolic disease. Corporate venture stakes are typically minority positions that do not grant exclusivity, so a portfolio company is free to partner elsewhere. Orbis having both Lilly money and a Novo alliance signals that two sophisticated buyers examined its chemistry.

Will Orbis actually receive $1.4 billion?

Only if the programs succeed. In discovery-stage alliances, most of the headline total is contingent on preclinical, clinical, regulatory and sales milestones reached years after signing. The near-term economics are typically research funding and an upfront payment. Many such collaborations never reach the later milestone tranches at all.

How did Novo and Lilly shares close?

Novo last closed at 41.71, down 1.93% on the day, with a range of 41.47 to 42.72. Eli Lilly last closed at 1137.82, up 0.15%, ranging between 1132.63 and 1151.23. Those are the most recent traded prices as of 20:00 GMT on 16 September 2026, with the market closed.

What should investors watch next?

Three things: whether Orbis's platform generates macrocycles that hit the agreed cardiometabolic targets, whether those molecules achieve oral bioavailability rather than injection-only dosing, and whether Novo expands the target list or exercises additional options. An expansion would be the clearest confirmation the chemistry is working.

Sources

• Lilly-backed Orbis does up to $1.4B macrocycle deal with Novo — Endpoints News

Photo: Edward Jenner · Pexels Licence — source